International Stem Cell (ISCO) reported strong FY18 revenues of $11.1m, up 48.7% compared with 2017 mainly due to the biomedical business, which had revenues of $9.3m, up 78.4% year-on-year. The profitability of the biomedical business continues to improve as well, with operating income of $3.3m, up 78.2% compared with the previous year. The company has also reported that the 12-patient Phase I trial of ISC-hpNSC in Parkinson’s disease (PD) is now fully enrolled with complete data expected in H120.
Written by
International Stem Cell |
A strong 2018 for the commercial business |
Financial update |
Pharma & biotech |
1 May 2019 |
Share price performance
Business description
Next events
Analysts
International Stem Cell is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
International Stem Cell (ISCO) reported strong FY18 revenues of $11.1m, up 48.7% compared with 2017 mainly due to the biomedical business, which had revenues of $9.3m, up 78.4% year-on-year. The profitability of the biomedical business continues to improve as well, with operating income of $3.3m, up 78.2% compared with the previous year. The company has also reported that the 12-patient Phase I trial of ISC-hpNSC in Parkinson’s disease (PD) is now fully enrolled with complete data expected in H120.
Year |
Revenue ($m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
7.5 |
(4.9) |
(1.19) |
0.0 |
N/A |
N/A |
12/18 |
11.1 |
(3.5) |
(0.54) |
0.0 |
N/A |
N/A |
12/19e |
13.0 |
(2.7) |
(0.36) |
0.0 |
N/A |
N/A |
12/20e |
14.1 |
(7.1) |
(0.88) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Strong sales
ISCO’s commercial operations leverage its human parthenogenetic stem cell (hpSC) technology and generate revenues to partially offset R&D spending for therapeutic development. Lifeline Skin Care (LSC) develops and sells skincare products and Lifeline Cell Technology (LCT) produces human cell culture products for testing. Together they generated $11.1m in sales in 2018, up 48.7% compared with last year and provided $2.4m in operating profit which was used to fund R&D.
LCT, the engine of the commercial business
LCT develops, manufactures and commercializes over 130 human cell culture products, including frozen human “primary” cells and the reagents (called media) needed to grow, maintain and differentiate the cells. Cell types include endothelial, epithelial, fibroblasts, melanocytes, stem and smooth muscle among others.
Final cohort of PD trial completed
The third and fourth patients in the third cohort of four patients have been successfully dosed. As a reminder, patients in the study are being treated in three cohorts with 30m, 50m and 70m stem cells, delivered via intracranial injection. The single-arm, open-label study is being conducted at the Royal Melbourne Hospital in Australia. Clinical assessments are scheduled at six and 12 months following surgery with complete data expected in H120.
Valuation: $43m or $5.75 per share
We have adjusted our valuation to $43m or $5.75 per basic share from $42m or $6.16 per basic share. The increase in total valuation is mainly due to rolling forward our NPV while the per share valuation decreased due to a higher share count. We project that the company will need at least $40m in additional financing before profitability in 2024 (down from $45m due to higher revenues and continued cost controls), of which an additional $3m will be required by the end of 2019.
Q418 results
The company reported strong FY18 revenues of $11.1m, up 48.7% compared with 2017 mainly due to the biomedical business, which had revenues of $9.3m, up 78.4% year-on-year. For the quarter, revenues were $2.2m, up 20.7% compared with Q417 mainly due to the biomedical business, which had quarterly revenues of $1.7m, up 43.4% compared with the same quarter last year. The cosmetics business, however, was down 19.7% for the year and now represents just 16.3% of total revenues compared with 30.3% in 2017. The operating profit of the commercial business increased 67.7% to $2.4m in 2018. For the company as a whole (including its therapeutics development programs), the operating loss was $3.5m for the year, down 29.7% from $4.9m in the previous year. We have made some adjustments to our model, decreasing our 2019 revenue estimate for the commercial business from $13.5m to $13.0m due to a slightly lower run rate than we modeled for the fourth quarter. We have kept SG&A roughly the same but reduced our 2019 R&D estimate to $2.5m from $6.5m due to continued cost controls at the company and the fact that the Phase I is now fully enrolled. We are also introducing 2020 estimates, including revenue of $14.1m, up 8.1% compared to our 2019 estimate.
Exhibit 1: Changes to estimates
$000s |
Revenue |
Operating profit |
Profit after tax |
||||||
Old |
New |
% change |
Old |
New |
% change |
Old |
New |
% change |
|
2019e |
13,483 |
12,999 |
(3.6%) |
(6,207) |
(4,008) |
35.4% |
(7,009) |
(4,491) |
35.9% |
2020e |
N/A |
14,057 |
N/A |
N/A |
(6,173) |
N/A |
N/A |
(7,296) |
N/A |
Source: Edison Investment Research. Note: Operating profit and profit after tax exclude amortization of acquired intangibles, exceptional items and share-based payments.
The company had $1.1m in cash on the balance sheet at the end of 2018. There was $2.0m in a related-party payable stemming from a promissory note that provided cash to the company from its co-chairman and CEO, with the note due and payable on 15 January 2019. Subsequent to the quarter end, the company entered into a conversion agreement to convert $1.0m of the note into 599,222 shares, with the remaining $1.0m now due on 15 January 2020. We project that the company will need at least $40m in additional financing before profitability in 2024 (down from $45m due to continued cost controls), of which an additional $3m will be required by the end of 2019.
Valuation
We have adjusted our valuation to $43m or $5.75 per basic share from $42m or $6.16 per basic share. The increase in valuation is mainly due to rolling forward our NPV while the per share valuation decreased due to a higher share count.
Exhibit 2: International Stem Cell valuation
Product |
Status |
Launch |
Peak sales ($m) |
NPV ($m) |
Probability |
rNPV ($m) |
NPV/share ($/share) |
Cosmetic and biomedical business |
Commercial |
Current |
18 |
35 |
90% |
31 |
4.17 |
Parkinson’s disease (royalties at 12% of sales) |
Phase I/IIa |
2024 |
2,800 |
592 |
7.5% |
44 |
5.92 |
G&A expense - after tax |
100% |
(32) |
(4.21) |
||||
Net cash |
(1.0) |
100% |
(1.0) |
(0.13) |
|||
Valuation |
|
|
|
626 |
|
43 |
5.75 |
Source: Edison Investment Research
One key risk to remember stems from the capital structure, which potentially creates sizeable dilution risk for minority investors. To date, ISCO has relied primarily on funds from management in the form of a combination of convertible preferred shares, warrants and options to fund its growth so that on a fully diluted basis management controls a significant portion of the company. While management has not converted the bulk of its sizeable holdings investors need to consider the possibility of significant dilution risk at some point in the future. There remain approximately 14.4m potentially dilutive shares from 4.0m warrants, 4.4m options and 6.1m convertible preferred shares in addition to the 7.5m common shares outstanding. Also, investors should note that the convertible preferred shares are subject to anti-dilution provisions under certain circumstances, creating further dilution potential.
Exhibit 3: Financial summary
US$000 |
2017 |
2018 |
2019e |
2020e |
||
Year end 31 December |
GAAP |
GAAP |
GAAP |
GAAP |
||
PROFIT & LOSS |
||||||
Revenue |
|
|
7,456 |
11,089 |
12,999 |
14,057 |
Cost of Sales |
(2,122) |
(4,069) |
(4,550) |
(4,920) |
||
Gross Profit |
5,334 |
7,020 |
8,449 |
9,137 |
||
Research and development |
(2,658) |
(2,396) |
(2,500) |
(6,500) |
||
EBITDA |
|
|
(4,616) |
(3,166) |
(2,200) |
(5,865) |
Operating Profit (before amort. and except.) |
(4,942) |
(3,474) |
(2,508) |
(6,173) |
||
Intangible Amortisation |
0 |
0 |
0 |
0 |
||
Exceptionals |
0 |
0 |
0 |
0 |
||
Other |
(1,127) |
1,343 |
0 |
0 |
||
Operating Profit |
(6,069) |
(2,131) |
(2,508) |
(6,173) |
||
Net Interest |
0 |
0 |
(240) |
(880) |
||
Profit Before Tax (norm) |
|
|
(4,942) |
(3,474) |
(2,748) |
(7,053) |
Profit Before Tax (reported) |
|
|
(6,069) |
(2,131) |
(2,748) |
(7,053) |
Tax |
0 |
0 |
0 |
0 |
||
Profit After Tax (norm) |
(4,942) |
(3,474) |
(2,748) |
(7,053) |
||
Profit After Tax (reported) |
(6,069) |
(2,131) |
(2,748) |
(7,053) |
||
Average Number of Shares Outstanding (m) |
4.2 |
6.4 |
7.7 |
8.0 |
||
EPS - normalised ($) |
|
|
(1.19) |
(0.54) |
(0.36) |
(0.88) |
EPS - normalised fully diluted ($) |
|
|
(1.46) |
(0.33) |
(0.36) |
(0.88) |
EPS - reported ($) |
|
|
(1.46) |
(0.33) |
(0.36) |
(0.88) |
Dividend per share (c) |
0.0 |
0.0 |
0.0 |
0.0 |
||
Gross Margin (%) |
71.5 |
63.3 |
65.0 |
65.0 |
||
EBITDA Margin (%) |
N/A |
N/A |
N/A |
N/A |
||
Operating Margin (before GW and except.) (%) |
N/A |
N/A |
N/A |
N/A |
||
BALANCE SHEET |
||||||
Fixed Assets |
|
|
4,009 |
4,026 |
4,428 |
4,849 |
Intangible Assets |
2,922 |
2,674 |
2,996 |
3,318 |
||
Tangible Assets |
1,013 |
1,274 |
1,354 |
1,453 |
||
Investments |
74 |
78 |
78 |
78 |
||
Current Assets |
|
|
2,855 |
3,770 |
5,363 |
6,613 |
Stocks |
1,307 |
1,501 |
2,321 |
2,509 |
||
Debtors |
465 |
651 |
928 |
1,003 |
||
Cash |
304 |
1,075 |
1,572 |
2,557 |
||
Other |
779 |
543 |
543 |
543 |
||
Current Liabilities |
|
|
(4,800) |
(5,077) |
(4,094) |
(3,136) |
Creditors |
(4,800) |
(3,032) |
(3,094) |
(3,136) |
||
Short term borrowings |
0 |
(2,045) |
(1,000) |
0 |
||
Long Term Liabilities |
|
|
0 |
(182) |
(3,000) |
(11,000) |
Long term borrowings |
0 |
0 |
(3,000) |
(11,000) |
||
Other long term liabilities |
0 |
(182) |
0 |
0 |
||
Net Assets |
|
|
2,064 |
2,537 |
2,697 |
(2,674) |
CASH FLOW |
||||||
Operating Cash Flow |
|
|
(2,142) |
(1,082) |
(1,553) |
(4,406) |
Net Interest |
0 |
0 |
(240) |
(880) |
||
Tax |
0 |
0 |
0 |
0 |
||
Capex |
(864) |
(661) |
(710) |
(729) |
||
Acquisitions/disposals |
0 |
0 |
0 |
0 |
||
Financing |
3,200 |
514 |
1,000 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
||
Net Cash Flow |
194 |
(1,229) |
(1,503) |
(6,015) |
||
Opening net debt/(cash) |
|
|
(110) |
(304) |
970 |
2,428 |
HP finance leases initiated |
0 |
0 |
0 |
0 |
||
Other |
0 |
(45) |
45 |
0 |
||
Closing net debt/(cash) |
|
|
(304) |
970 |
2,428 |
8,443 |
Source: Edison Investment Research, company reports
|
|
Research: Industrials
Management flagged stronger Q4 trading, in line with its expectations. Netherlands soil remediation activities require regulatory approval and a prudent stance has been taken over resuming shipments there, which is the primary driver of our significant estimate reduction. In this light, the steps being taken for debt management, including a proposed dividend reduction, are entirely logical. Renewi’s rating is at depressed levels – we feel due to earnings uncertainty and higher debt levels – but potential resolutions to both issues are visible. The company is still yielding 4.4%.